Company Profile

1910 Genetics Inc
Profile last edited on: 10/7/22      CAGE: 893V4      UEI: MGASA78GBGP3

Business Identifier: Utilizing AI to accelerate design of small molecule and protein therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

451 D Street
Boston, MA 02210
   (603) 540-0485
Location: Single
Congr. District: 08
County: Suffolk

Public Profile

1910 Genetics is a biotechnology company integrating AI, computation, and biological automation to improve drug development: the design of small molecule and protein therapeutics. The firm is structured around decreasing the time and cost factor in drug development while also improving the success rate of achieving effective drugs: innovative medicines needed by patients. Currently, two drug discovery engines are in use enabling the design both of small molecule and of protein therapeutics not, so far, yet utilized in AI drug discovery space. Current focus of applying the firm's novel drug discovery approach involves several areas of investigation: neuroscience, infectious disease, immunology and oncology. With two drug discovery engines - ELVIS™ and ROSALYND™ - enabling the design of both small molecule and protein therapeutics -- an unmatched capability in the AI drug discovery space - the firm's therapeutic "area-agnostic, end-to-end technology" powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization. At this point, the firm's technology andapproach to drug discovery address several areas including, but not limited to, neuroscience, infectious disease, immunology and oncolo

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $546,376
Project Title: Development of selective calpain-1 inhibitors for chronic pain

Key People / Management

  Jennifer O Nwankwo -- Founder & CEO

  Jennifer Bordeau -- Associate Director of Business Operations & Finance

  Shannon Cosgrove -- Research Scientist

  Austin Day -- AI Research Scientist III

  Ken Fang -- Medicinal Chemistry Consultant

  Brandon Moore -- Head of AI Research & ML Engineering

  Anthony Navarro Sr -- Manager, Laboratory Operations, Compound Management, and Automation

  Seun Olorunwunmi -- Software Engineer

  Aesha Upadhyay -- Research Associate

Company News

There are no news available.